期刊文献+

伤寒Vi结合疫苗的研究 被引量:7

Preparation and characteristic of typhoid Vi conjugate vaccine
原文传递
导出
摘要 目的制备伤寒Vi结合疫苗并研究其特性。方法载体蛋白质重组铜绿假单胞菌外毒素A(rEPA)经ADH衍生后,与伤寒Vi多糖结合制备结合物,并对结合物进行化学特性和生物学特性的研究,尤其是研究结合物对小鼠的免疫原性。结果制备的伤寒Vi结合物相对分子质量(Mr)明显大于游离的伤寒Vi多糖和载体蛋白质,其多糖和蛋白质比值为1.2,结合物含量测定证明至少有70%的多糖是以结合状态存在,HPLC(TSK5000)的结果显示伤寒Vi结合物中Kd(partition coefficient)≤0.2占94%,内毒素含量、过敏原性、豚鼠和小鼠的动物毒性试验等都证明结合物安全,免疫双扩散试验证明结合物的多糖和蛋白质组分的抗原性都完好保持,在小鼠上的免疫原性试验证明结合物具有与单纯Vi多糖完全不同的免疫学特性,可以产生更高的特异性免疫应答,并具有明显的加强免疫效果。结论按试验设计方案制备的伤寒Ⅵ结合疫苗,经化学和生物学检测,证明结合物确以多糖蛋白质结合状态存在,并证实该结合物具有较好的生物安全性和免疫学效果。 Objective To prepare a typhoid Vi conjugate vaccine and investigate its characteristics. Methods Recombinant exoprotein A(rEPA) of Pseudomonas aeruginosa was derived with adipic acid dihydrazide (ADH) and bound to the capsular polysaccharide of Salmonella typhi (Vi). The conjugates were analyzed with proper chemical and biological methods. Immunogenicity of the conjugates was tested in particular in mice model. Results The conjugates were much larger in size than polysaccharide and cartier protein alone. The Vi/protein ratio (wt/wt) was 1.2 and more than 70% of Vi stayed in conjugate form. Analysis of HPLC(TSK5000) showed that the conjugates with Kd( partition coefficient) ≤ 0.2 occupied 94%. Endotoxin content, anaphylactoid test, abnormal toxicity test in guinea pigs and mice gave evidence of the safety of the conjugates. Double-immunodiffusion demonstrated that both Vi and rEPA in the conjugates kept intact immunogerticity. Immunogerticity test in mice showed that the conjugates could induce significant responses, and elicit boosted responses while Vi not. Conclusion Vi conjugate vaccine was successsfully developed. It was safe and got strong immunngenicity in mice.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第7期665-668,共4页 Chinese Journal of Microbiology and Immunology
关键词 伤寒 结合疫苗 特性 Typhoid Conjugates vaccine Characteristic
  • 相关文献

参考文献10

  • 1Ivanoff B,Levine MM,Albert PH.Vaccination against typhoid fever:present status.Bull WHO,1994,72(6):957-971.
  • 2Acharya IL,Tapa R,Gurubacharya VL,et al.Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi:a preliminary report.N Engl J Med,1987,317:1101-1104.
  • 3Klugman KP,Gilbertson I,Kornhof HJ,et al.Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.Lancet ii,1987,1165-1169.
  • 4王志高,周伟忠,史鉴宝,王同来,谢广中,辜清吾,王秉瑞,王立亚,王洪飞,丁兆松,杨跃,沈玉霖,王薇媛,王祥初.伤寒Vi多糖菌苗流行病学效果[J].江苏预防医学,1996,7(3):13-16. 被引量:11
  • 5Yang HH,Wu CG,Xie GZ,et al.Efficacy trial of Vi polysaccharide vaccine against typhoid fever in South-Western China.Bull WHO,2001,79(7):625-631.
  • 6SZU SC,Li XR,Stone AL,et al.Relation between structure and immunologic properties of the Vi capsular polysaccharide.Infect Immun,1991,59:4555-4561.
  • 7Kossaczka Z,Lin FY,Ho VA,et al.Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults,teenagers,and 2-to 4-year-old children in Vietnam.Infect Immun,1999,67:5806-5810.
  • 8Lin FY,Ho VA,Khiem HB,et al.The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to five-year-old children.N Engl J Med,2001,344:1263-1269.
  • 9Lanh MN,Lin FY,Bay PV,et al.Persistence of antibodies and efficacy against typhoid fever 28-46 months following Vi conjugate vaccines (VirEPA) in 2 to 5 years-old children.N Engl J Med,2003,349:1390-1391.
  • 10Canh DG,Lin FY,Thiem VD,et al.Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2-to 5-year-old Vietnamese children.Infect Immun,2004,72:6586-6588.

共引文献10

同被引文献126

引证文献7

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部